Andrew R. Morton

Andrew R. Morton

Auto-generated profile, based on publicly available information

Andrew R. Morton

Department of Stem Cell Biology and Regenerative Medicine, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2019 in Cell
Verified
Journal Article
Closed access
AMAndrew R. Morton
Andrew R. Morton
NDNergiz Dogan-Artun
Nergiz Dogan-Artun
ZFZachary J. Faber
Zachary J. Faber
GMGraham MacLeod
Graham MacLeod
CBCynthia F. Bartels
Cynthia F. Bartels
PSPeter C. Scacheri
Peter C. Scacheri

1 November 2019 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
ZDZhen Dong
Zhen Dong
GZGuoxin Zhang
Guoxin Zhang
MQMeng Qu
Meng Qu
RGRyan C. Gimple
Ryan C. Gimple
QWQiulian Wu
Qiulian Wu
JRJeremy N. Rich
Jeremy N. Rich
Glioblastomas are highly lethal cancers, containing self-renewing glioblastoma stem cells (GSC). Here, we show that GSCs, differentiated glioblastoma cells (DGC), and nonmalignant brain cultures all displayed robust circadian rhythms, yet GSCs alone displayed exquisite dependence on core clock transcription factors, BMAL1 and CLOCK, for optimal cell growth. Downregulation of BMAL1 or CLOCK in GSCs induced cell-cycle arrest and apoptosis. Chromatin immunoprecipitation revealed that BMAL1 preferentially bound metabolic genes and was associated with active chromatin regions in GSCs compared with neural stem cells. Targeting BMAL1 or CLOCK attenuated mitochondrial metabolic function and reduced expression of tricarboxylic acid cycle enzymes. Small-molecule agonists of two independent BMAL1–CLOCK negative regulators, the cryptochromes and REV-ERBs, downregulated stem cell factors and reduced GSC growth. Combination of cryptochrome and REV-ERB agonists induced synergistic antitumor efficacy. Collectively, these findings show that GSCs co-opt circadian regulators beyond canonical circadian circuitry to promote stemness maintenance and metabolism, offering novel therapeutic paradigms. Significance: Cancer stem cells are highly malignant tumor-cell populations. We demonstrate that GSCs selectively depend on circadian regulators, with increased binding of the regulators in active chromatin regions promoting tumor metabolism. Supporting clinical relevance, pharmacologic targeting of circadian networks specifically disrupted cancer stem cell growth and self-renewal. This article is highlighted in the In This Issue feature, p. 1469

1 April 2018 in Cell Stem Cell
Verified
Journal Article
Closed access
XWXiuxing Wang
Xiuxing Wang
BPBriana C. Prager
Briana C. Prager
QWQiulian Wu
Qiulian Wu
LKLeo J.Y. Kim
Leo J.Y. Kim
RGRyan C. Gimple
Ryan C. Gimple
JRJeremy N. Rich
Jeremy N. Rich

20 December 2017 in Nature
Verified
Journal Article
Closed access
PDF file
SMStephen C. Mack
Stephen C. Mack
Kristian W. PajtlerKristian W. Pajtler
Kristian W. Pajtler
LCLukas Chavez
Lukas Chavez
KOKonstantin Okonechnikov
Konstantin Okonechnikov
KBKelsey C. Bertrand
Kelsey C. Bertrand
JRJeremy N. Rich
Jeremy N. Rich

5 July 2017 in Nature
Verified
Journal Article
Open access
PDF file
TMTyler E. Miller
Tyler E. Miller
BLBrian B. Liau
Brian B. Liau
LWLisa C. Wallace
Lisa C. Wallace
AMAndrew R. Morton
Andrew R. Morton
QXQi Xie
Qi Xie
JRJeremy N. Rich
Jeremy N. Rich
An in vivo RNA interference screening strategy in glioblastoma enabled the identification of a host of epigenetic targets required for glioblastoma cell survival that were not identified by parallel standard screening in cell culture, including the transcription pause–release factor JMJD6, and could be a powerful tool to uncover new therapeutic targets in cancer. Most high-throughput target discovery screens for glioblastoma have been limited to in vitro models with uncertain physiological relevance. Here, Jeremy Rich and colleagues perform two parallel RNA interference screens for transcriptional regulators, comparing an in vitro screen in cell lines to an in vivo screen that recapitulates the tumour microenvironment. They find several transcriptional elongation factors that are specifically required for glioblastoma cell survival in vivo, particularly the transcriptional pause release factor JMJD6 which is highly expressed in gliomas. This type of in vivo functional screen has the potential to uncover novel therapeutic targets for cancer that have not been identified in previous in vitro approaches. Glioblastoma is a universally lethal cancer with a median survival time of approximately 15 months1. Despite substantial efforts to define druggable targets, there are no therapeutic options that notably extend the lifespan of patients with glioblastoma. While previous work has largely focused on in vitro cellular models, here we demonstrate a more physiologically relevant approach to target discovery in glioblastoma. We adapted pooled RNA interference (RNAi) screening technology2,3,4 for use in orthotopic patient-derived xenograft models, creating a high-throughput negative-selection screening platform in a functional in vivo tumour microenvironment. Using this approach, we performed parallel in vivo and in vitro screens and discovered that the chromatin and transcriptional regulators needed for cell survival in vivo are non-overlapping with those required in vitro. We identified transcription pause–release and elongation factors as one set of in vivo-specific cancer dependencies, and determined that these factors are necessary for enhancer-mediated transcriptional adaptations that enable cells to survive the tumour microenvironment. Our lead hit, JMJD6, mediates the upregulation of in vivo stress and stimulus response pathways through enhancer-mediated transcriptional pause–release, promoting cell survival specifically in vivo. Targeting JMJD6 or other identified elongation factors extends survival in orthotopic xenograft mouse models, suggesting that targeting transcription elongation machinery may be an effective therapeutic strategy for glioblastoma. More broadly, this study demonstrates the power of in vivo phenotypic screening to identify new classes of ‘cancer dependencies’ not identified by previous in vitro approaches, and could supply new opportunities for therapeutic intervention.

7 August 2019 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
XWXiuxing Wang
Xiuxing Wang
KYKailin Yang
Kailin Yang
QWQiulian Wu
Qiulian Wu
LKLeo J. Y. Kim
Leo J. Y. Kim
AMAndrew R. Morton
Andrew R. Morton
JRJeremy N. Rich
Jeremy N. Rich
Concurrent targeting of pyrimidine synthesis and oncogenic driver pathways improves therapeutic efficacy in glioblastoma.